Among these, chemoimmunotherapy has entered everyday clinical practice as new first-line therapy in metastatic TNBC patients with PD-L1 overexpression (tumours with ≥1% PD-L1 expression in immune cells) or an elevated Combined Positive Score (CPS) [10]. This evidence concerns the gene CD274 and neoplasm.